ES2721907T3 - Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal - Google Patents

Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal Download PDF

Info

Publication number
ES2721907T3
ES2721907T3 ES12832845T ES12832845T ES2721907T3 ES 2721907 T3 ES2721907 T3 ES 2721907T3 ES 12832845 T ES12832845 T ES 12832845T ES 12832845 T ES12832845 T ES 12832845T ES 2721907 T3 ES2721907 T3 ES 2721907T3
Authority
ES
Spain
Prior art keywords
renal
prognosis
diagnosis
compositions
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12832845T
Other languages
English (en)
Spanish (es)
Inventor
Joseph Anderberg
Jeff Gray
Paul Mcpherson
Kevin Nakamura
James Patrick Kampf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astute Medical Inc
Original Assignee
Astute Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astute Medical Inc filed Critical Astute Medical Inc
Application granted granted Critical
Publication of ES2721907T3 publication Critical patent/ES2721907T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Surgery (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pregnancy & Childbirth (AREA)
ES12832845T 2011-08-26 2012-08-24 Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal Active ES2721907T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161528003P 2011-08-26 2011-08-26
US201161528000P 2011-08-26 2011-08-26
PCT/US2012/052298 WO2013043310A1 (en) 2011-08-26 2012-08-24 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Publications (1)

Publication Number Publication Date
ES2721907T3 true ES2721907T3 (es) 2019-08-06

Family

ID=47914751

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12832845T Active ES2721907T3 (es) 2011-08-26 2012-08-24 Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal

Country Status (16)

Country Link
US (2) US9459261B2 (2)
EP (2) EP2748605B1 (2)
JP (2) JP2014529073A (2)
KR (1) KR20140074307A (2)
CN (2) CN103874923B (2)
AU (1) AU2012312907A1 (2)
BR (1) BR112014004389A2 (2)
CA (1) CA2846602A1 (2)
EA (1) EA201490384A1 (2)
ES (1) ES2721907T3 (2)
IN (1) IN2014MN00377A (2)
MX (1) MX346096B (2)
PL (1) PL2748605T4 (2)
PT (1) PT2748605T (2)
TR (1) TR201903235T4 (2)
WO (1) WO2013043310A1 (2)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2836218T3 (es) 2008-10-21 2021-06-24 Astute Medical Inc Procedimientos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
WO2011075744A1 (en) 2009-12-20 2011-06-23 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ605698A (en) 2010-06-23 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
PT2748605T (pt) * 2011-08-26 2019-05-03 Astute Medical Inc Processos e composições para o diagnóstico e o prognóstico de lesões renais e de insuficiência renal
US10935548B2 (en) 2011-12-08 2021-03-02 Astute Medical, Inc. Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2
EP3361255B1 (en) 2013-01-17 2020-03-11 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US10983136B2 (en) * 2013-01-28 2021-04-20 Diasorin S.P.A. Use of 1,25-dihydroxyvitamin D values in ratio with PTH as a prognostic biomarker
US11261257B2 (en) 2013-01-28 2022-03-01 Diasorin S.P.A. Methods for detecting 1,25-dihydroxyvitamin D and related antibodies
ES2696075T3 (es) 2013-01-28 2019-01-14 Diasorin S P A Procedimiento y kit para detectar 1,25-dihidroxivitamina D y anticuerpos relacionados
CN110007084B (zh) 2013-12-03 2022-11-18 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
CA2965153C (en) 2014-10-20 2023-10-24 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2973653A1 (en) * 2015-01-18 2016-07-21 Diasorin S.P.A. Use of 1,25-dihydroxyvitamin d values in ratio with pth as a prognostic biomarker
US11243202B2 (en) 2015-04-09 2022-02-08 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN105466984B (zh) * 2016-01-14 2018-12-28 郑以山 用于肾脏非显性损伤的预警装置及其使用方法
EP3465201A4 (en) 2016-06-06 2020-08-26 Astute Medical, Inc. MANAGEMENT OF ACUTE KIDNEY DAMAGE USING INSULINOMIMETIC GROWTH FACTOR BINDING PROTEIN 7 AND TISSUE METALLOPROTEINASE 2 INHIBITOR
EP4063853A1 (en) 2017-01-12 2022-09-28 Astute Medical, Inc. Methods and compositions for evaluation and treatment of renal injury and renal failure based on c-c motif chemokine ligand 14 measurement
CN110431422A (zh) 2017-02-06 2019-11-08 机敏医药股份有限公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
CN110709103B (zh) 2017-04-05 2024-02-02 机敏医药股份有限公司 用于生物学样品中具有改善的性能的timp2的测定法
KR20210019459A (ko) 2018-05-24 2021-02-22 레니버스 테라퓨틱스, 인크. 신장 손상 및 신부전 위험이 있는 환자를 치료하는 방법
CN109251956A (zh) * 2018-09-18 2019-01-22 青岛大学 糖尿病大鼠胰岛内MyD88 mRNA表达及黄芪的调节作用
WO2020092909A1 (en) * 2018-11-02 2020-05-07 Prevencio, Inc. Prognostic and diagnostic methods for risk of acute kidney injury
CN114113575B (zh) * 2020-08-28 2023-06-02 菲鹏生物股份有限公司 标记复合物及其制备方法与应用
CN116434960B (zh) * 2023-06-13 2023-10-13 中国人民解放军总医院 一种心源性休克临床决策支持系统、设备及可存储介质
WO2025033619A1 (ko) * 2023-08-07 2025-02-13 경상국립대학교병원 신 대체요법 개시 결정을 위한 정보 제공 방법 및 이의 결정을 위한 말기 신질환 진단용 조성물

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
AU1772992A (en) 1991-04-10 1992-11-17 Biosite Diagnostics Incorporated Crosstalk inhibitors and their uses
JP3290988B2 (ja) 1991-04-11 2002-06-10 バイオサイト・ダイアグノスティックス・インコーポレイテッド 多重リガンドを同時検出する新規接合体及び検定法
US5324634A (en) * 1992-03-31 1994-06-28 The Research Foundation Of State University Of New York Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
MXPA05010385A (es) * 2003-03-27 2006-03-08 Childrens Hosp Medical Center Metodo y estuche para detectar el inicio temprano de lesion celular tubular renal.
CN1791797A (zh) * 2003-03-27 2006-06-21 儿童医院医疗中心 用于检测肾小管细胞损伤的早发的方法和试剂盒
US7560244B2 (en) * 2003-06-04 2009-07-14 Joslin Diabetes Center, Inc. Method of evaluating a subject for risk or predisposition of reduced renal function over time
US20050272101A1 (en) 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
US20060003345A1 (en) * 2004-06-30 2006-01-05 Pfizer Inc RNA bioassay
CN101557825A (zh) * 2005-08-19 2009-10-14 森托科尔公司 抗蛋白酶解的抗体制剂
WO2007144781A2 (en) * 2006-04-21 2007-12-21 Diagnotech Pty. Ltd. Diagnostic methods and kits utilizing antibodies for metalloproteases
EP2479569A3 (en) * 2007-03-26 2012-09-26 Novartis AG Predictive renal safety biomarkers and biomarker signatures to monitor kidney function
CN101910845A (zh) * 2007-11-15 2010-12-08 比奥波托诊断股份公司 个体分子形式的生物标志的诊断用途
KR20100122495A (ko) 2008-02-29 2010-11-22 고쿠리츠 다이가쿠 호우징 나고야 다이가쿠 급성 신장 장해 및 예후 추정용 바이오마커 및 그 용도
JP2012501456A (ja) * 2008-08-28 2012-01-19 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後のための方法および組成物
EP2324354B1 (en) * 2008-08-29 2014-07-16 Astute Medical, Inc. Methods for prognosis of acute renal failure
ES2836218T3 (es) * 2008-10-21 2021-06-24 Astute Medical Inc Procedimientos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
EP2913676A1 (en) * 2008-11-10 2015-09-02 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9229010B2 (en) * 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2010279249B2 (en) * 2009-02-06 2015-08-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2763948C (en) * 2009-06-02 2019-03-12 Biocrates Life Sciences Ag Combination of amino acids, acylcarnitines and biogenic amines for the assessment of chronic kidney disease
US20130045494A1 (en) * 2009-09-18 2013-02-21 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX2009012633A (es) * 2009-11-23 2011-05-24 Univ Mexico Nacional Autonoma Metodo de diagnostico para detectar la lesion renal aguda a traves del uso de la proteina de choque termico de 72 kda como un biomarcador sensible.
WO2011075744A1 (en) * 2009-12-20 2011-06-23 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ701807A (en) * 2010-02-26 2015-05-29 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
PT2748605T (pt) * 2011-08-26 2019-05-03 Astute Medical Inc Processos e composições para o diagnóstico e o prognóstico de lesões renais e de insuficiência renal

Also Published As

Publication number Publication date
US20140213477A1 (en) 2014-07-31
EP2748605A4 (en) 2015-12-02
WO2013043310A1 (en) 2013-03-28
PT2748605T (pt) 2019-05-03
US9459261B2 (en) 2016-10-04
BR112014004389A2 (pt) 2017-03-28
EP2748605B1 (en) 2018-12-05
KR20140074307A (ko) 2014-06-17
US9784750B2 (en) 2017-10-10
PL2748605T3 (pl) 2019-08-30
CN103874923A (zh) 2014-06-18
MX2014002146A (es) 2014-08-21
US20170016917A1 (en) 2017-01-19
AU2012312907A1 (en) 2014-03-13
CN103874923B (zh) 2016-09-14
JP2017032586A (ja) 2017-02-09
NZ706242A (en) 2016-07-29
CN106443011A (zh) 2017-02-22
JP2014529073A (ja) 2014-10-30
IN2014MN00377A (2) 2015-06-19
EP2748605A1 (en) 2014-07-02
TR201903235T4 (tr) 2019-03-21
PL2748605T4 (pl) 2019-08-30
NZ621716A (en) 2016-04-29
CA2846602A1 (en) 2013-03-28
MX346096B (es) 2017-03-07
EP3489690A1 (en) 2019-05-29
EA201490384A1 (ru) 2014-08-29

Similar Documents

Publication Publication Date Title
ES2721907T3 (es) Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
NZ705411A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CL2013003605A1 (es) Metodo para la evaluacion del riesgo de un evento tromboembólico en un sujeto que comprende determinar la presencia de serpin a 10 (inhibidor de la proteina z); kit que comprende reactivos para detectar serpin a 10.
MX351779B (es) Prediccion de neoplasmas neuroendocrinos gastroenteropancreaticos (gep-nens).
EP3734280A3 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ES2570380T3 (es) Método para determinar la aptitud de inhibidores de EZH2 humano en tratamiento
MX2014003153A (es) Prediccion de riesgo de evento cardiovascular y usos del mismo.
NZ598712A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX2016001719A (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
MX360236B (es) Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.
NZ605698A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AR097542A1 (es) Métodos y sistemas para la evaluación de la permeabilidad y la porosidad de la roca y la composición de los fluidos
MX2013014153A (es) Biomarcadores paa terapia de inhibidor de hedgehog.
AR060320A1 (es) Metodo para identificar y localizar problemas en losetas de drenaje
MX2015012303A (es) Un metodo no invasivo para medir el estres oxidativoy daño oxidativo de los biomarcadores cutaneos.
MX386919B (es) Composiciones, métodos y kits para el diagnóstico de una neoplasia neuroendocrina gastroenteropancreática.
TR201903974T4 (tr) Tasnif makinesi için otomatik kusur tanı metodu ve cihazı.
EA201500080A1 (ru) Способ in vitro диагностирования и мониторинга рака
CY1122360T1 (el) Μεθοδος για τη διαγνωση της νοσου niemann-pick
NZ606124A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX2015009914A (es) Dispositivos de recogida de sangre que contienen aditivos de inhibicion de la via de contacto.
BR112016016101A2 (pt) Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos
MX383423B (es) Método in vitro para el diagnóstico del síndrqme del intestino irritable y la enfermedad inflamatoria intestinal.
BR112018067292A2 (pt) métodos e composições para a detecção e o diagnóstico de doença renal e doença periodontal
NZ594772A (en) Diagnosis and prognosis of renal injury and renal failure using vitamin k dependent protein c